BSX · 10-Q · 2026Q3 · Full report
Operating Cash Flow and Capex
BOSTON SCIENTIFIC CORP · 2026-11-02 · Importance 25 · Surprise 32 · In source text
Operating cash flow was $2.870 billion in the first nine months of 2026, down $301 million from the prior-year period, primarily because of increased working-capital payments. Investing activities used $2.984 billion, including $930 million of net payments for acquisitions, $1.545 billion for investments and acquisitions of technologies, and $552 million for property, plant, equipment, and internal-use software. The $1.545 billion investment amount primarily related to MiRus LLC. The company also reported net cash payments for acquisitions primarily related to Nalu Medical and Scivita Medical Technology.
Key facts
- Operating cash flow was $2.870 billion in the first nine months of 2026, down $301 million from the prior-year period, primarily due to higher working-capital payments, partly offset by higher sales and operating income. source
- Boston Scientific spent $552 million on property, plant, equipment, and internal-use software in the first nine months of 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -1.2% | Boston Scientific spent $552 million on property, plant, equipment, and internal-use software in the first nine months of 2026. |
| cash | negative | realized | -0.7% | Operating cash flow was $2.870 billion in the first nine months of 2026, down $301 million from the prior-year period, primarily due to… |